Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis
PROTEOMICS – Clinical Applications · 2026-07 · 20 (4)
DOI: 10.1002/prca.70047 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, online erschienen am 29.05.2026. Verfasst von Anna Negroni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biotechnologies, ENEA, Casaccia Research Center, Rome, Italy. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Proteomics, Feces. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project ECS 0000024 Rome Technopole, - CUP B83C22002820006, National Recovery and Resilience Plan (NRRP), Mission 4, Component 2 Investment 1.5, funded from the European Union - NextGenerationEU.
Abstract (Originalsprache)
Background and aims Non‐alcoholic Fatty Liver Disease (NAFLD) affects about a quarter of the world's population. Liver biopsy remains the gold standard for diagnosing the progressive form of NAFLD called Non‐alcoholic Steatohepatitis (NASH) but it is invasive, prone to sampling errors and observer variability, and impractical for widespread use. Fecal non‐invasive biomarkers have emerged as a new approach to diagnose, stage, and monitor NAFLD over time.
Methods
Proteomic analysis was performed using Liquid Chromatography‐Mass Spectrometry (LC‐MS/MS) in fecal samples derived from mice fed with high fat and sugar diet representing NAFLD model and with the addition of 5 cycles of dextran‐sulphate in drinking water to induce a NASH.
Results
Qualitative and quantitative different protein profiles resulted in a comparison between the three groups of mice. An enrichment analysis of differentially expressed proteins explores the molecular pathways involved. A selection of the most significant modulated proteins between groups was performed. The proteins Transthyretin, Kallikrein1 and Trefoil Factor 3 were validated by ELISA.
Conclusion
Our exploratory discovery study identified several proteins that, alone or in combination, enable a good separation between NASH, NAFLD and healthy mice, highlighting their potential as key targets for future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Biotechnologies, ENEA, Casaccia Research Center, Rome, Italy.
- Departmental Faculty of Medicine and Surgery, UniCamillus - Saint Camillus International University of Health Sciences, Rome, Italy.
- IRCCS San Camillo Hospital, Venice, Italy.
- Nanofaber S.r.l., Rome, Italy.
- Department For Sustainability, Division Sustainable Materials, ENEA, Casaccia Research Centre, Rome, Italy.
ORCID-Profile: Luisa Pieroni, Mariateresa Mancuso, Roberta Vitali
Förderung
- Project ECS 0000024 Rome Technopole, - CUP B83C22002820006
- National Recovery and Resilience Plan (NRRP), Mission 4, Component 2 Investment 1.5, funded from the European Union - NextGenerationEU
Zitieren
APA
Negroni, A., Pieroni, L., Fiaschini, N., Palone, F., Mancuso, M., & Vitali, R. (2026). Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis. PROTEOMICS – Clinical Applications, 20(4). https://doi.org/10.1002/prca.70047
Vancouver
Negroni A, Pieroni L, Fiaschini N, Palone F, Mancuso M, Vitali R. Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis. PROTEOMICS – Clinical Applications. 2026;20(4). doi:10.1002/prca.70047
BibTeX
@article{Negroni2026,
author = {Negroni, Anna and Pieroni, Luisa and Fiaschini, Noemi and Palone, Francesca and Mancuso, Mariateresa and Vitali, Roberta},
title = {Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis},
journal = {PROTEOMICS – Clinical Applications},
year = {2026},
volume = {20},
number = {4},
doi = {10.1002/prca.70047}
}
EUVIMED